


Series in
Dermatological
Treatment

PHOTOTHERAPY TREATMENT PROTOCOLS

THIRD EDITION



Steven R. Feldman
Michael D. Zanolli

 CRC Press
Taylor & Francis Group

PHOTOTHERAPY TREATMENT PROTOCOLS

Series in Dermatological Treatment

Series editors

Steven R Feldman

and

Peter van de Kerkhof

Published in association with the *Journal of Dermatological Treatment*

1. Robert Baran, Roderick Hay, Eckhart Haneke, Antonella Tosti
Onychomycosis, second edition, ISBN 9780415385794
2. Ronald Marks
Facial Skin Disorders, ISBN 9781841842103
3. Sakari Reitamo, Thomas Luger, Martin Steinhoff
Textbook of Atopic Dermatitis, ISBN 9781841842462
4. Calum C Lyon, Amanda J Smith
Abdominal Stomas and Their Skin Disorders, Second Edition, ISBN 9781841844312
5. Leonard Goldberg
Atlas of Flaps of the Face, ISBN 9781853177262
6. Antonella Tosti, Maria Pia De Padova, Kenneth Beer
Acne Scars: Classification and Treatment, ISBN 9781841846873
7. Bertrand Richert, Nilton di Chiacchio, Eckart Haneke
Nail Surgery, ISBN 9780415472333
8. Giuseppe Micali, Francesco Lacarrubba
Dermatoscopy in Clinical Practice: Beyond Pigmented Lesions, ISBN 9780415468732
9. Steven R Feldman, Michael D Zanolli
Phototherapy Treatment Protocols, Third Edition, ISBN 9781498754620

PHOTOTHERAPY TREATMENT PROTOCOLS

THIRD EDITION

The methods of

Steven R. Feldman M.D., Ph.D.

Wake Forest University School of Medicine
Winston-Salem, NC, USA

and

Michael D. Zanolli M.D.

Nashville, TN, USA
Past President of The Photomedicine Society



CRC Press

Taylor & Francis Group

Boca Raton London New York

CRC Press is an imprint of the
Taylor & Francis Group, an **informa** business

CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742

© 2016 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works

Printed on acid-free paper
Version Date: 20160510

International Standard Book Number-13: 978-1-4987-5462-0 (Paperback)

This book contains information obtained from authentic and highly regarded sources. While all reasonable efforts have been made to publish reliable data and information, neither the author[s] nor the publisher can accept any legal responsibility or liability for any errors or omissions that may be made. The publishers wish to make clear that any views or opinions expressed in this book by individual editors, authors or contributors are personal to them and do not necessarily reflect the views/opinions of the publishers. The information or guidance contained in this book is intended for use by medical, scientific or health-care professionals and is provided strictly as a supplement to the medical or other professional's own judgement, their knowledge of the patient's medical history, relevant manufacturer's instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures or diagnoses should be independently verified. The reader is strongly urged to consult the relevant national drug formulary and the drug companies' and device or material manufacturers' printed instructions, and their websites, before administering or utilizing any of the drugs, devices or materials mentioned in this book. This book does not indicate whether a particular treatment is appropriate or suitable for a particular individual. Ultimately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as to advise and treat patients appropriately. The authors and publishers have also attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Visit the Taylor & Francis Web site at
<http://www.taylorandfrancis.com>

and the CRC Press Web site at
<http://www.crcpress.com>

TABLE OF CONTENTS

Acknowledgments	ix
Introduction to the Third Edition	xi
Introduction to the Second Edition	xiii
Introduction to the First Edition	xv
Warning	xix
National Psoriasis Foundation	xxi
1. Psoriasis	
Ultraviolet B Phototherapy by Minimal Erythema Dose	1
Patient Instructions.....	1
Protocol.....	3
Ultraviolet B Phototherapy by Skin Type	7
Patient Instructions.....	7
Protocol.....	8
Narrowband Ultraviolet B Phototherapy by MED	11
Patient Instructions.....	11
Protocol.....	12
Narrowband Ultraviolet B Phototherapy by Skin Type	16
Patient Instructions.....	16
Protocol.....	17
Systemic Psoralen plus Ultraviolet A.....	20
Patient Instructions.....	20
Protocol.....	22
Topical Psoralen plus Ultraviolet A.....	25
Patient Instructions for Psoralen Bath (or Soak) plus Ultraviolet A.....	25
Protocol.....	27
Patient Instructions for Psoralen Paint (Lotion) plus Ultraviolet A	29
Protocol.....	30
Retinoid plus Ultraviolet B Phototherapy	32
Patient Instructions.....	32
Protocol.....	33
Retinoid plus Narrowband Ultraviolet B	36
Patient Instructions.....	36
Protocol.....	38
Retinoid plus Psoralen plus Ultraviolet A	41
Patient Instructions.....	41
Protocol.....	43
Goeckerman Treatment (Crude Coal Tar plus UVB).....	46
Patient Instructions.....	46
Protocol.....	48
Ingram Treatment (Anthralin plus UVB)	51
Patient Instructions.....	51
Protocol.....	53
Localized Delivery of Ultraviolet B	56
Patient Instructions for Excimer Laser at 308 nm Wavelength.....	56
Protocol.....	57
Patient Instructions for Handheld UVB Devices	59
Protocol.....	60

Home Narrowband Ultraviolet B Phototherapy	62
Candidates for Home Phototherapy	62
Selection of Patients	62
Patient Instructions	64
Protocol	65
Specialized Treatments	68
Protocol for Hand and/or Foot Treatments	68
Patient Instructions for Scalp Debridement	69
Patient Instructions for Hydrosound Bath	71
Reference	72
2. Vitiligo	
Narrowband Ultraviolet B Phototherapy	73
Patient Instructions	73
Protocol	75
Localized Delivery of Ultraviolet (UVB) Excimer Laser at 308 nm	
Wavelength	77
Patient Instructions	77
Protocol	78
Handheld Devices	79
Patient Instructions	79
Protocol	80
Systemic Psoralen plus Ultraviolet A Treatment	81
Patient Instructions	81
Protocol	83
Psoralen Baths or Soaks plus Ultraviolet A (Bath PUVA)	85
Patient Instructions	85
Protocol	86
Psoralen Lotion plus Ultraviolet A (Paint PUVA)	88
Patient Instructions	88
Protocol	89
3. Atopic Dermatitis	
Ultraviolet B Phototherapy	91
Patient Instructions	91
Protocol	93
Combination Ultraviolet A/B Phototherapy	96
Patient Instructions	96
Protocol	97
Narrowband Ultraviolet B Phototherapy	100
Patient Instructions	100
Protocol	101
Systemic Psoralen plus Ultraviolet A	103
Patient Instructions	103
Protocol	105
Hydrosound Bath	108
Patient Instructions	108
Protocol	109
4. Pruritus	
Ultraviolet B Phototherapy	111
Patient Instructions	111
Protocol	113
Combination Ultraviolet A/B Phototherapy	116
Patient Instructions	116
Protocol	117

	Narrowband Ultraviolet B Phototherapy	120
	Patient Instructions.....	120
	Protocol.....	121
5.	Cutaneous T-Cell Lymphoma	
	Ultraviolet B Phototherapy	123
	Patient Instructions.....	123
	Protocol.....	125
	Narrowband Ultraviolet B (NBUVB) Phototherapy by Skin Type.....	128
	Patient Instructions.....	128
	Protocol.....	129
	Systemic Psoralen plus Ultraviolet A Treatment.....	131
	Patient Instructions.....	131
	Protocol.....	133
6.	Scleroderma and Other Sclerosing Disorders	
	Broad Band Ultraviolet A Phototherapy by Fixed Dose	137
	Patient Instructions.....	137
	Protocol.....	139
	Ultraviolet A1 (UVA1) Phototherapy by Fixed Dose	141
	Patient Instructions.....	141
	Protocol.....	142
	Reference	143
7.	Other Phototherapy-Responsive Dermatologic Diseases That May Be Treated with Selected Protocols	
	UVB Protocol for Atopic Dermatitis.....	145
	Narrowband UVB Protocol for CTCL.....	145
	PUVA Protocol for CTCL.....	146
8.	Patient Consent Forms	
	Ultraviolet B Phototherapy Consent	147
	Narrowband Ultraviolet B (NBUVB) Phototherapy Consent	149
	Psoralen plus Ultraviolet A (PUVA) Consent.....	151
	Scalp Treatments Consent	153
	Home Ultraviolet Therapy Consent.....	155
9.	Patient Educational Handouts	
	Ultraviolet B Phototherapy Patient Information	157
	Systemic PUVA Patient Information	159
	Topical Bath/Paint PUVA Patient Information	160
	Goekerman Regimen Patient Information	161
	Modified Ingram Patient Information	162
10.	Treatment Management Forms	
	Physician's Orders.....	163
	Treatment Record.....	164
	Ophthalmology Exam Record	165
	Self-Administered Psoriasis Area and Severity Scoring Instructions.....	166
	Self-Administered Psoriasis Area and Severity Scoring Sheet	168
	Doctor-Administered Psoriasis Area and Severity Scoring Instructions.....	170
	Flow Sheets PUVA	171
	Methotrexate	172
	Retinoid	173
	Cyclosporine.....	174

Appendix: Skin Types

Procedure for Determination of the Minimal
Erythema Dose (MED) for UVB..... 175

Procedure for Determination of the Minimal
Erythema Dose (MED) for Narrowband UVB 176

Differential Diagnosis 178

Some Agents That May Cause Photosensitivity 180

Equipment Manufacturers (Not Exclusive)..... 182

Letter for Home Phototherapy Treatment..... 183

Suggested Reading 185

Index..... 187

ACKNOWLEDGMENTS

The authors thank terrific dedicated phototherapists Bobbie Oliver, Sharon Sharp, Beverly Webb, and Barbara Brown, RN, for their advice and skillful, compassionate care of patients. The efforts of the National Psoriasis Foundation on behalf of all our patients with psoriasis cannot go unnoticed. Finally, the authors thank Taylor & Francis Group for their tireless support in the development of this manual.



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

INTRODUCTION TO THE THIRD EDITION

The treatment of psoriasis has evolved dramatically since the last edition. The introduction of tumor necrosis factor inhibitors revolutionized the treatment of psoriasis. Then came an interleukin-12/interleukin-23 inhibitor that only requires one injection every 3 months, about equal in efficacy to the strongest of the tumor necrosis factor inhibitors. And now, in interleukin-17 inhibitors, we have even more potent treatments. Moreover, the safety of these new systemic treatments knocks the socks off the former gold-standard systemic treatments of the past, methotrexate and cyclosporine.

But biologics are expensive and should only be used in patients who need them. For patients with psoriasis or other diseases that can be effectively treated with phototherapy, biologics may not be required. In an era of constantly increasing focus on reducing the cost of disease management, phototherapy—which has fallen to the side in the wake of biologic excitement—may be poised for resurgence. The array of phototherapy options—from whole body and targeted phototherapy in the office to home phototherapy—remain a valuable, effective, safe, and cost-effective way to manage a host of skin conditions.

We hope this manual helps give you the tools you need to make phototherapy more accessible to your patients.

Steven R. Feldman



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

INTRODUCTION TO THE SECOND EDITION

The basic premise concerning the therapeutic option of phototherapy remains the same for the second edition as with our first edition. The first sentence of the introduction to the first edition reads: "The availability of phototherapy in a dermatology practice enables the practitioner to provide a broader range of therapeutic options." I encourage the persons utilizing the protocols contained in this book to read through the Introduction to the First Edition to enable them to have a better understanding of the application of therapeutic ultraviolet light therapy for inflammatory diseases. The continued modifications of protocols, although minimal in most circumstances, demonstrate the ongoing refinement of ultraviolet light delivery to maintain therapeutic efficacy while minimizing possible side effects.

New delivery systems for ultraviolet light, whether in the form of laser or localized ultraviolet B light, have been an advancement in the application of phototherapy for the same diseases that are treated with whole body phototherapy. The incorporation of protocols for localized delivery enables even more utility for treatment with ultraviolet light to the affected areas while sparing the clinically normal skin. The localized delivery technology brings with it a shift in the approach to treatment. Instead of limiting the dose energy delivered to the whole body in order to minimize the possible side effects of ultraviolet light to uninvolved skin, the areas to be treated are given multiples of the minimal erythema dose to produce the most rapid and effective clearing of the diseased skin. In addition, while treating specialized diseases such as vitiligo with localized ultraviolet light, the dose can be adjusted to use lower amounts of light to depigmented areas without enhancing the contrast with surrounding normal skin. The addition of protocols using localized delivery of ultraviolet light is an important aspect of this new second edition.

The effects of ultraviolet light on the skin continue to be a source of new insight into the physiology and pathophysiology as related to the broader field of photobiology and photomedicine. I remain fascinated by the continued developments in this field that help us to understand why ultraviolet light is such a beneficial therapy for inflammatory dermatosis of the skin. There are clearly differences in the effects in the skin with delivery of high-dose ultraviolet light at various wavelengths when compared to lower doses of ultraviolet light. As with the more recent advent of protein immune modifiers for the treatment of psoriasis, the "biologics," the effects of ultraviolet light in low doses serve to modify the skin's immune mechanisms and help decrease the activity of psoriasis. Further insights into the complex interactive pathways of the cutaneous immune system will not only help to refine therapeutic intervention but will also add to the understanding of the pathophysiology of the disease. Use of these protocols for treatment of responsive skin diseases is in effect application

of “photobiologic” therapy. The continued use of ultraviolet light by medical specialists will remain an option for therapeutic intervention for chronic inflammatory skin diseases.

Michael D. Zanolli
Steven R. Feldman

INTRODUCTION TO THE FIRST EDITION

The availability of phototherapy in a dermatology practice enables the practitioner to provide a broader range of therapeutic options. This is especially true for those dermatologists who treat a large number of inflammatory dermatoses, particularly psoriasis. The development of a phototherapy unit, even if it is just a single ultraviolet light cabinet, will serve not only the patients in a particular practice, but can also serve as a regional referral center. Smaller communities surrounding such a location would tend to refer to a local center rather than having the patients undertake time-consuming drives two or three times a week for phototherapy at a less convenient site in a large urban setting.

There are many textbooks concerning photomedicine, photobiology, and therapeutic applications for ultraviolet light (see Suggested Reading). These are invaluable for understanding the scientific underpinning of phototherapy and the development of the protocols contained in this manual. The expertise of the physician concerning the proper delivery of ultraviolet light treatments for a particular patient or a particular disease is essential to obtaining the best outcomes. The physician should also serve as the resource for information concerning medical aspects of phototherapy. This manual provides a practical basis for phototherapy protocols and consent forms that can be modified or adjusted by the physician to meet the specific needs of specific patients.

In addition to the important role played by the physician in determining treatment regimens, special training on the part of the phototherapy nurses and technicians has become more important for the continuity of care and for determining the standard of care for any particular region. Essential to any phototherapy location are the expert nursing efforts necessary to carry through the implementation of the protocols and to be vigilant for signs, especially early subtle signs, of phototoxic reactions and other possible side effects during the course of therapy. Physicians should strongly consider the benefits of using another practical resource for psoriasis patient education: the National Psoriasis Foundation.

The genesis and development of this phototherapy manual occurred because of the need to have available on site a standard of the protocols for delivery of medical treatments for compliance with local and federal regulations. This is particularly true for a hospital-based phototherapy treatment center. This compilation of treatment protocols is not meant to be absolute, comprehensive, or construed as the only method for delivery of care. The protocols continue to be in a state of development and modification to better improve the response to therapy and, it is hoped, to decrease the frequency of side effects. Another factor that enters into the modifications of phototherapy protocols is the advent of newer technology, such as narrowband UVB or the use of psoralen medications other than 8-methoxypsoralen in the future. The use of phototherapy and enhancement of therapeutic response must always take into consideration the risk of side effects from the particular modality of treatment, both short and long term.

The original protocol manual was devised at the Bowman-Gray School of Medicine, Wake Forest University Medical Center, for its Psoriasis Day Care Center in 1986. Many changes in the overall treatment of psoriasis have occurred since that time, such as outpatient Goeckerman treatment being used much less frequently than 10 years ago. The new treatments include use of systemic retinoids, immunosuppressive treatments, and topical vitamin D₃ analogues and retinoids, often in combination with phototherapy. There are still centers at which the Goeckerman or modified Ingram treatments for psoriasis are the mainstay of their facilities. However, more outpatient treatments and increased use of combination therapy with ultraviolet light and topical therapy or ultraviolet light and systemic therapy bring the outpatient treatment of psoriasis back to dermatologists' offices. This eliminates the need for large outlays of capital for the development of treatment centers that would occupy 1000–1500 ft² in order to provide the facilities necessary for day-care treatments, bath facilities, lounge areas, and multiple treatment rooms.

This text is meant to be an office-based manual that can be used as the office procedure manual. It can be referred to on a daily basis by the phototherapy technicians, as well as used as a resource if any questions arise about the standards of care within an office. We encourage you to make and modify copies of the consent forms and other documents and use them for patients in your practice.

This manual is not meant to be a rigid text. The protocols have undergone and continue to undergo their own genesis. Modifications or additions to the text for delivery of ultraviolet light for a particular disease or variations between skin types that best suit the practitioner can be done to the main body of the text with minimal effort. The manual also can be used as a basis for treatment of photoresponsive diseases that are not individually listed or do not have sections devoted to them. Other entities reported in dermatological literature as responsive to ultraviolet light therapy would include eosinophilic folliculitis, granuloma annulare, graft vs. host disease, certain forms of lichen planus, and, of course, variations on the parapsoriasis group of disorders, such as large plaque parapsoriasis and/or common pityriasis rosea. The basis for treatment of these disorders and necessary protocols for the phototherapy technicians or nurses to follow can be derived by the local site and kept on file for reference.

One of the basic principles to be understood when selecting ultraviolet therapy, whether in the form of UVB or photochemotherapy with PUVA, is each disease entity may not and should not be treated exactly alike. The phototherapy for psoriasis differs from the approach to therapy for a mild case of pityriasis rosea. In general, phototherapy can be therapeutic even when used in a nonerythemogenic modality, and this is particularly true when dealing with forms of photochemotherapy. Therefore, the manual has extreme flexibility, and the most common of the photoresponsive dermatoses are listed with fairly specific protocols that have been used for the past 14 years with methods that have been modified through experience and found to be successful. Other dermatoses may also be treated with a different dosage and frequency of therapy for a specific disorder. For example, the treatment modality for atopic dermatitis with UVA/UVB combination therapy may also be used to treat eosinophilic folliculitis. The protocol for treatment of generalized granuloma annulare may also be adopted from the treatment protocol used for cutaneous T-cell lymphoma. The understanding and the insights into the photobiology associated with the changes of improvement in the inflammatory dermatoses

are also going to continue to be more delineated as time goes on. This manual can serve as the source of defined protocols for the delivery of therapeutic ultraviolet light and can be modified to treat those other dermatoses that may not be corticosteroid responsive, without the need for systemic immunosuppressive therapy in many cases.

The development and modifications of this manual, initially at Wake Forest University Medical Center, then at the Vanderbilt Phototherapy Treatment Center, have only been possible and brought to light because of the continuing efforts of the dedicated physicians and personnel at both institutions. The requests of practicing dermatologists for such a manual have been the moving force behind getting this project to the dermatology community. More important are the benefits to the patients who can now receive phototherapy closer to home and through their own dermatologists' offices. The overall use of phototherapy as an office procedure can be very rewarding for practitioners because of the broad range of dermatoses that have been reported as being responsive to therapeutic intervention with ultraviolet light treatment. In my opinion, the gratification of being able to deliver a therapeutic option, which is so beneficial to patients with photoresponsive dermatoses, will make providing such treatment a satisfying part of any busy dermatology practice.

Michael D. Zanolli



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

WARNING

Narrowband UVB protocols use more energy (joules) than broadband protocols. *Do not* use the narrowband protocols with broadband equipment as serious harm could result.



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

NATIONAL PSORIASIS FOUNDATION

Dermatologists offering phototherapy should keep in mind the National Psoriasis Foundation (NPF), a terrific resource for our psoriasis patients. The NPF has great patient education resources, with a wide variety of brochures available free (digitally) to doctors to help educate patients about phototherapy and their other treatment options. It supports the specialty of dermatology by working with insurers and regulators to assure patients have access to dermatologists and to psoriasis treatments. The Foundation can also help with a critical issue for dermatologists setting up a phototherapy unit: the education of the phototherapist through NPF-sponsored courses. The NPF has been an invaluable resource to the editors of this book.

The Foundation's resources are freely accessible at www.psoriasis.org. We encourage all health care professionals caring for patients with psoriasis to join the Foundation as professional members.